Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer

We designed a single-arm, open label phase II study to determine the efficacy and toxicity of the combination of pazopanib with CapeOx (capecitabine and oxaliplatin) in metastatic /recurrent advanced gastric cancer (AGC) patients. Previously untreated AGC patients received capecitabine (850 mg/m(2)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Kim, Seung Tae, Lee, Jeeyun, Lee, Su Jin, Park, Se Hoon, Jung, Sin-Ho, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Park, Joon Oh
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5029686/
https://ncbi.nlm.nih.gov/pubmed/27003363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8175
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars